Steven O’Day, MD
The John Wayne Cancer Institute
Dr. O’Day, MD has been at the forefront of new drug development in melanoma and most recently played a leadership role in the development of the breakthrough immune checkpoint inhibitor ipilimumab as well as the anti-PD1 antibodies pembrolizamab and nivolumab. Dr. O’Day has been a principal investigator on over 100 clinical trials including several large, international phase 3 trials. Dr. O’Day is the Professor of Medical Oncology, Director of Immuno-Oncology, Director of Research at The John Wayne Cancer Institute at Providence St. John’s Health Center. Dr. O’Day received his medical training at Johns Hopkins in Baltimore and the Dana Farber Cancer Institute in Boston.
Caroline Robert, MD, PhD
Dr. Robert is a scientist of international renown in the clinical and translational research of melanoma and the cutaneous side effects of new, targeted chemotherapies. She is head of the Dermatology Unit at the Institut Gustave-Roussy, Paris, France and previously was medical director for Johnson & Johnson Consumer Europe. Dr. Robert received her medical degree at the Cochin Port-Royal School of Medicine, Paris, followed by French Board Certification in dermatology. She completed a research fellowship at Harvard University and a PhD in cancer immunology and immunotherapy.
Triple Negative Breast Cancer
Javier Cortés, MD, PhD
Ramón y Cajal University Hospital
Dr. Cortes is the Head of the Breast Cancer and Gynecological Tumor Programs at the Ramon y Cajal University Hospital in Madrid and Investigator of the Breast Cancer Research Program at Vall d’Hebron Institute of Oncology in Barcelona. He has authored more than 140 papers in peer-reviewed journals with a focus on breast cancer and new therapeutic products. Dr. Cortés received a degree in Medicine and Surgery from the Universidad Autónoma de Madrid and was awarded the title of Doctor in Medical Oncology from the University of Navarra.
Joyce O’Shaughnessy, MD
Texas Oncology | Baylor Sammons Cancer Center | US Oncology Network
Dr. O’Shaughnessy is the Celebrating Women Chair in Breast Cancer Research at Baylor-Sammons Cancer Center and Chair of Breast Cancer Research for The US Oncology Network. She specializes in breast medical oncology. She is a Diplomate of the American Board of Internal Medicine. Dr. O’Shaughnessy focuses on her practice and clinical research on breast cancer treatment. She received her M.D. from Yale University Medical School.
Non-Small Cell Lung Cancer
Roy S. Herbst, MD, PhD
Yale Comprehensive Cancer Center | Yale School of Medicine | Smilow Cancer Hospital
Dr. Herbst is Ensign Professor of Medicine, Professor of Pharmacology, Chief of Medical Oncology, Director of the Thoracic Oncology Research Program, and Associate Director for Translational Research at Yale Cancer Center (YCC) and Yale School of Medicine, with an active practice at Smilow Cancer Hospital, New Haven, Connecticut. He received his medical degree from Cornell University Medical College and a PhD in Molecular Cell Biology from Rockefeller University. Dr. Herbst’s laboratory work focuses non-small cell lung cancer (NSCLC), specifically on immunotherapy angiogenesis, EGFR/VEGFR inhibition in NSCLC and targeting KRAS-activated pathways.
Fred Hirsch, MD, PhD
University of Colorado School of Medicine
Dr. Hirsch is a Professor of Medicine and Pathology at the University of Colorado School of Medicine. His research interests include translational research, biomarkers and targeted therapies, and early detection of lung cancer. He is also the Chief Executive Officer of the International Association for the Study of Lung Cancer. Dr. Hirsch is co-chair for SWOG Lung Correlative Science Committee and a member of the World Health Organization’s Expert Panel on the International Classification of Lung Tumours. He was a recent member of the National Cancer Institute’s Thoracic Steering Committee and Cancer Therapy Evaluation Program, Intergroup Correlative Science Committee. Dr. Hirsch received a MD and PhD, from the University of Copenhagen, Denmark.